Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Sarcoma Research
Published in: Clinical Sarcoma Research 1/2013

Open Access 01-12-2013 | Case Report

Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis

Authors: Juan Martin-Liberal, Charlotte Benson, Heather McCarty, Khin Thway, Christina Messiou, Ian Judson

Published in: Clinical Sarcoma Research | Issue 1/2013

Login to get access

Abstract

Background

Desmoid tumours/aggressive fibromatosis (DT/AF) are infrequent soft-tissue neoplasms. They usually behave as indolent diseases. However, they may grow locally infiltrating or compressing adjacent structures. The role of local treatment is limited and only a few drugs have shown activity.

Cases presentation

We report the outcome of two patients affected by progressive DT/AF treated with the angiogenesis inhibitor pazopanib in two different institutions. Both patients achieved dramatic improvement in their symptoms and radiological signs of response. The clinical benefit lasted for more than 1 year and it is still ongoing.

Conclusions

Pazopanib is an active treatment in DT/AF. It is the first time this has been reported.
Appendix
Available only for authorised users
Literature
1.
Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ: Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol. 1997, 6 (2): 98-101. 10.1097/00019606-199704000-00005CrossRefPubMed
2.
Biermann JS: Desmoid tumors. Curr Treat Options Oncol. 2000, 1 (3): 262-266. 10.1007/s11864-000-0038-5CrossRefPubMed
3.
Bertagnolli MM, Morgan JA, Fletcher CD, Raut CP, Dileo P, Gill RR, Demetri GD, George S: Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer. 2008, 44 (16): 2404-2410. 10.1016/j.ejca.2008.06.038CrossRefPubMed
4.
Bonvalot S, Desai A, Coppola S, Le Péchoux C, Terrier P, Dômont J, Le Cesne A: The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. 2012, 23 (Suppl 10): 158-166. 10.1093/annonc/mds298.CrossRef
5.
Smith AJ, Lewis JJ, Merchant NB, Leung DH, Woodruff JM, Brennan MF: Surgical management of intra-abdominal desmoid tumours. Br J Surg. 2000, 87 (5): 608-613. 10.1046/j.1365-2168.2000.01400.xCrossRefPubMed
6.
Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA: Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999, 17 (1): 158-167.PubMed
7.
Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G: High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004, 100 (3): 612-620. 10.1002/cncr.11937CrossRefPubMed
8.
Deyrup AT, Tretiakova M, Montag AG: Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer. 2006, 106 (1): 208-213. 10.1002/cncr.21553CrossRefPubMed
9.
Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I: Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009, 45 (17): 2930-2934. 10.1016/j.ejca.2009.08.016CrossRefPubMed
10.
Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA: Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006, 24 (7): 1195-1203. 10.1200/JCO.2005.04.0717CrossRefPubMed
11.
Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, Guillemet C, Chevreau C, Cupissol D, Chabaud S, Jimenez M, Duffaud F, Piperno-Neumann S, Mignot L, Blay JY: Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011, 22 (2): 452-457. 10.1093/annonc/mdq341CrossRefPubMed
12.
Gounder MM, Lefkowitz RA, Keohan ML, D'Adamo DR, Hameed M, Antonescu CR, Singer S, Stout K, Ahn L, Maki RG: Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011, 17 (12): 4082-4090. 10.1158/1078-0432.CCR-10-3322PubMedCentralCrossRefPubMed
13.
Li M, Cordon-Cardo C, Gerald WL, Rosai J: Desmoid fibromatosis is a clonal process. Hum Pathol. 1996, 27 (9): 939-943. 10.1016/S0046-8177(96)90221-XCrossRefPubMed
14.
Martin-Liberal J, Judson I, Benson C: Antiangiogenic approach in soft-tissue sarcomas. Expert Rev Anticancer Ther. 2013, 13 (8): 975-982. 10.1586/14737140.2013.820579CrossRefPubMed
15.
Potti A, Ganti AK, Tendulkar K, Sholes K, Chitajallu S, Koch M, Kargas S: Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol. 2004, 130 (1): 52-56. 10.1007/s00432-003-0504-0CrossRefPubMed
16.
Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W: Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol. 1999, 125 (10): 577-581. 10.1007/s004320050319CrossRefPubMed
17.
Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM: Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg. 2004, 91 (2): 242-247. 10.1002/bjs.4398CrossRefPubMed
18.
Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B: Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001, 8 (3): 260-267. 10.1007/s10434-001-0260-9CrossRefPubMed
19.
Iyoda A, Hiroshima K, Baba M, Fujisawa T, Yusa T, Ohwada H: Expression of vascular endothelial growth factor in thoracic sarcomas. Ann Thorac Surg. 2001, 71 (5): 1635-1639. 10.1016/S0003-4975(01)02533-4CrossRefPubMed
20.
George D: Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol. 2001, 28 (5 Suppl 17): 27-33. 10.1053/sonc.2001.29185.CrossRefPubMed
21.
Négrier S, Raymond E: Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs. 2012, 30 (4): 1791-1801. 10.1007/s10637-011-9677-6CrossRefPubMed
22.
Savage DG, Antman KH: Imatinib mesylate–a new oral targeted therapy. N Engl J Med. 2002, 346 (9): 683-693. 10.1056/NEJMra013339CrossRefPubMed
23.
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, : Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012, 379 (9829): 1879-1886. 10.1016/S0140-6736(12)60651-5CrossRefPubMed
Metadata
Title
Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
Authors
Juan Martin-Liberal
Charlotte Benson
Heather McCarty
Khin Thway
Christina Messiou
Ian Judson
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Clinical Sarcoma Research / Issue 1/2013
Electronic ISSN: 2045-3329
DOI
https://doi.org/10.1186/2045-3329-3-13

Other articles of this Issue 1/2013

Clinical Sarcoma Research 1/2013 Go to the issue

Research

MicroRNA expression in Epstein-Barr virus-associated post-transplant smooth muscle tumours is related to leiomyomatous phenotype

Case Report

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib

Review

Mesenchymal stem cell transformation and sarcoma genesis

Research

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study

Research

Gastrointestinal stromal tumors: a case-only analysis of single nucleotide polymorphisms and somatic mutations

Research

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits